Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Inhibrx Appoints Dr. Carlos Bais As Chief Scientific Officer and David Matly As President

PRIVATEApr 01, 2025•about 1 year ago

Position

Chief Scientific Officer

Company

Inhibrx

Carlos Bais

San DiegoBiotechnologyTherapeuticsBiopharma

Description

Inhibrx Biosciences announces the appointment of Dr Carlos Bais as the new Chief Scientific Officer and promotes David Matly to President. This follows the departure of Dr Brendan Eckelman from the company.

Company Information

Company

Inhibrx

Location

11025 N. TORREY PINES ROAD, SUITE 200

San Diego, California, United States

About

Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Inhibrx's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months